< em > Circ_0053943 < /em > complexed with IGF2BP3 drives uveal melanoma progression via regulating N6-methyladenosine modification of < em > Epidermal growth factor receptor < /em >
In this study, we identified a novel circRNA, circ_0053943, through re-analysis of UM microarray data and quantitative RT-PCR. Circ_0053943 was found to be upregulated in UM and to promote the proliferation and metastatic ability of UM cells in both in vitro and in vivo settings. Mechanistically, circ_0053943 was observed to bind to the KH1 and KH2 domains of insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3), thereby enhancing the function of IGF2BP3 by stabilizing its target mRNA. RNA sequencing assays identified epidermal growth factor receptor (EGFR) as a target gene of circ_0053943 and IGF2BP3 at the transc...
Source: Oncology Research - April 30, 2024 Category: Cancer & Oncology Authors: Andi Zhao Yue Wang Zijin Wang Qing Shao Q I Gong Hui Zhu Shiya Shen H U Liu Xuejuan Chen Source Type: research
Targeting brain tumors with innovative nanocarriers: bridging the gap through the blood-brain barrier
CONCLUSION: This review also provides deep insights into recent advancements in nanocarrier-based formulations and technologies for GBM management. Elucidation of various scientific advances in conjunction with encouraging findings concerning the future perspectives and challenges of nanocarriers for effective brain tumor management has also been discussed.PMID:38686045 | PMC:PMC11056000 | DOI:10.32604/or.2024.047278 (Source: Oncology Research)
Source: Oncology Research - April 30, 2024 Category: Cancer & Oncology Authors: Karan Wadhwa Payal Chauhan Shobhit Kumar Rakesh Pahwa Ravinder Verma Rajat Goyal Govind Singh Archana Sharma Neha Rao Deepak Kaushik Source Type: research
The Epstein-Barr virus-miRNA-BART6-5p regulates TGF- β/SMAD4 pathway to induce glycolysis and enhance proliferation and metastasis of gastric cancer cells
CONCLUSION: In this study, we found that EBV-miRNA-BART6-5p can target SMAD4, effectively increasing glycolysis in gastric cancer cells by regulating the TGF-β/SMAD4 signaling pathway, thereby enhancing the proliferation and metastasis of gastric cancer cells. Our findings may offer new insights into the metabolic aspects of gastric cancer.PMID:38686046 | PMC:PMC11055990 | DOI:10.32604/or.2024.046679 (Source: Oncology Research)
Source: Oncology Research - April 30, 2024 Category: Cancer & Oncology Authors: Xuhui Zhao Xiaomin Huang Chunyan Dang Xia Wang Yujiao Qi Hongling Li Source Type: research
Hydroxysafflor yellow A induced ferroptosis of Osteosarcoma cancer cells by HIF-1 α/HK2 and SLC7A11 pathway
Oncol Res. 2024 Apr 23;32(5):899-910. doi: 10.32604/or.2023.042604. eCollection 2024.ABSTRACTOsteosarcoma is a very serious primary bone cancer with a high death rate and a dismal prognosis. Since there is no permanent therapy for this condition, it is necessary to develop a cure. Therefore, this investigation was carried out to assess the impacts and biological functions of hydroxysafflor yellow A (HYSA) in osteosarcoma cell lines (MG63). In this investigational study, MG63 cells were utilized. Microarray experiments, quantitative polymerase chain reaction (qPCR), immunofluorescent staining, extracellular acidification ra...
Source: Oncology Research - April 30, 2024 Category: Cancer & Oncology Authors: Yiwen Zhu Liu Yang Ying Yu Ying Xiong Ping Xiao Xiao Fu Xin Luo Source Type: research
Deciphering resistance mechanisms and novel strategies to overcome drug resistance in ovarian cancer: a comprehensive review
Oncol Res. 2024 Apr 23;32(5):831-847. doi: 10.32604/or.2024.031006. eCollection 2024.ABSTRACTOvarian cancer is among the most lethal gynecological cancers, primarily due to the lack of specific symptoms leading to an advanced-stage diagnosis and resistance to chemotherapy. Drug resistance (DR) poses the most significant challenge in treating patients with existing drugs. The Food and Drug Administration (FDA) has recently approved three new therapeutic drugs, including two poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and niraparib) and one vascular endothelial growth factor (VEGF) inhibitor (bevacizumab) for ma...
Source: Oncology Research - April 30, 2024 Category: Cancer & Oncology Authors: Effat Alemzadeh Leila Allahqoli Afrooz Mazidimoradi Esmat Alemzadeh Fahimeh Ghasemi Hamid Salehiniya Ibrahim Alkatout Source Type: research
A genetic variant study of bortezomib-induced peripheral neuropathy in Chinese multiple myeloma patients
CONCLUSION: CYP2A6, EPHX1, MTHFR, ALDH1A1, HTR7, MME and BIPN are linked in Chinese MM patients. BIPN is more likely to occur in patients with lower MTHFR mRNA expression, which might result in higher serum Hcy levels.PMID:38686049 | PMC:PMC11055991 | DOI:10.32604/or.2023.043922 (Source: Oncology Research)
Source: Oncology Research - April 30, 2024 Category: Cancer & Oncology Authors: Yan Zhang Heyang Zhang Jing Wang Xin Wei Y I Qu Feng Xu Lijun Zhang Source Type: research
A comparative < em > in vitro < /em > study on the effect of SGLT2 inhibitors on chemosensitivity to doxorubicin in MCF-7 breast cancer cells
This study aimed to examine the synergistic cytotoxic and antitumor effects of SGLT2 inhibitors, specifically Canagliflozin (CAN), Dapagliflozin (DAP), Empagliflozin (EMP), and Doxorubicin (DOX), using in vitro experimentation. The precise combination of CAN+DOX has been found to greatly enhance the cytotoxic effects of doxorubicin (DOX) in MCF-7 cells. Interestingly, it was shown that cancer cells exhibit an increased demand for glucose and ATP in order to support their growth. Notably, when these medications were combined with DOX, there was a considerable inhibition of glucose consumption, as well as reductions in intra...
Source: Oncology Research - April 30, 2024 Category: Cancer & Oncology Authors: Shahid Karim Alanoud Naher Alghanmi Maha Jamal Huda Alkreathy Alam Jamal Hind A Alkhatabi Mohammed Bazuhair Aftab Ahmad Source Type: research
miR-200b-3p accelerates progression of pituitary adenomas by negatively regulating expression of RECK
This study investigated the molecular mechanism underlying miR-200b-3p regulation in pituitary adenomas to provide a theoretical basis for treatment. Bioinformatics was used to analyze pituitary adenoma-related genes and screen new targets related to RECK and miRNA. As well, the relationship between miR-200b-3p and RECK protein was verified using a double-luciferase reporter gene assay. The expression of miR-200b-3p in clinical samples was analyzed by in situ hybridization. Transfection of the miR-200b-3p inhibitor and small interfering-RECK (si-RECK) was verified by qPCR. GH3 cell viability and proliferation were detected...
Source: Oncology Research - April 30, 2024 Category: Cancer & Oncology Authors: Xiaoxi Wang Yanfei Jia Qiang Li Qiang Yang Yingfeng Liu Beifeng Wei Xiang Niu Yinjie Zhang Xiaodong Luo Ziyu Zhao Peng Wang Source Type: research
Metochalcone induces senescence-associated secretory phenotype via JAK2/STAT3 pathway in breast cancer
In this study, we found that TEC inhibited cell proliferation of breast cancer BT549 cells and lung cancer A549 cells in a concentration-dependent manner. TEC induced cell cycle arrest in the S-phase, cell migration inhibition in vitro, and reduced tumor growth in vivo. Moreover, transcriptomic analysis revealed that TEC modulated the activity of the JAK2/STAT3 and P53 pathways. TEC triggered the senescence-associated secretory phenotype (SASP) by repressing the JAK2/STAT3 axis. The mechanism of metochalcone against breast cancer depended on the induction of SASP via deactivation of the JAK2/STAT3 pathway, highlighting the...
Source: Oncology Research - April 30, 2024 Category: Cancer & Oncology Authors: Jianbo Zhou Feng Wan Bin Xiao Xin Li Cheng Peng F U Peng Source Type: research
Levels of evidence and grades of recommendation supporting European society for medical oncology clinical practice guidelines
CONCLUSION: One-third of the current ESMO CPG recommendations are supported by the highest level of evidence. More well-designed randomized clinical trials are needed to increase the proportion of LOE I and GOR A recommendations, ultimately leading to improved outcomes for cancer patients.PMID:38686053 | PMC:PMC11055998 | DOI:10.32604/or.2024.048948 (Source: Oncology Research)
Source: Oncology Research - April 30, 2024 Category: Cancer & Oncology Authors: Marko Skelin Bruna Perkov-Stipi čin Sanja Vu šković Marina Šandrk Plehaček Ane Ba šić David Šarčević Maja Ili ć Ivan Kre čak Source Type: research
Antitumor effects of a novel photosensitizer-mediated photodynamic therapy and its influence on the cell transcriptome
This study investigated the antitumor effects and mechanisms of a novel photosensitizer meso-5-[ρ-diethylene triamine pentaacetic acid-aminophenyl]-10,15,20-triphenyl-porphyrin (DTP) mediated PDT (DTP-PDT). Cell viability, reactive oxygen species (ROS), and apoptosis were measured with a Cell Counting Kit-8 assay, DCFH-DA fluorescent probe, and Hoechst staining, respectively. Cell apoptosis- and autophagy-related proteins were examined using western blotting. RNA sequencing was used to screen differentially expressed mRNAs (DERs), and bioinformatic analysis was performed to identify the major biological events after DTP-P...
Source: Oncology Research - April 30, 2024 Category: Cancer & Oncology Authors: Jingjing Chen Dan Wang Zequn Wang Mengyuan Han Houqing Yin Wenting Zhou Ribai Yan Yan Pan Source Type: research
Multi-cohort comprehensive analysis unveiling the clinical value and therapeutic effect of < em > GNAL < /em > in glioma
In this study, we aimed to investigate the role and relationship between OSPRGs and glioma. Univariate and multivariate Cox regression analyses were performed to assess the relationship between OSPRGs and the overall survival of glioma based on public cohorts, and the target gene (G Protein Subunit Alpha L, GNAL) was screened. The association of GNAL expression with clinicopathological characteristics, gene mutation landscape, tumor immune microenvironment (TIME), deoxyribonucleic acid (DNA) methylation, and naris-occlusion controlled genes (NOCGs) was performed. Immunohistochemistry was used to evaluate GNAL level in glio...
Source: Oncology Research - April 30, 2024 Category: Cancer & Oncology Authors: Zhen Liu Liangwang Yang Zhengxing Xie Hui Yu Tianyi Gu Daoming Shi Ning Cai Shenghua Zhuo Source Type: research
Targeting KRAS in pancreatic cancer
Oncol Res. 2024 Apr 23;32(5):799-805. doi: 10.32604/or.2024.045356. eCollection 2024.ABSTRACTPancreatic cancer has a dismal prognosis due to late detection and lack of efficient therapies. The Kirsten rat sarcoma virus (KRAS) oncogene is mutated in up to 90% of all pancreatic ductal adenocarcinomas (PDACs) and constitutes an attractive target for therapy. However, the most common KRAS mutations in PDAC are G12D (44%), G12V (34%) and G12R (20%) that are not amenable to treatment by KRAS G12C-directed cysteine-reactive KRAS inhibitors such as Sotorasib and Adagrasib that exhibit clinical efficacy in lung cancer. KRAS G12C mu...
Source: Oncology Research - April 30, 2024 Category: Cancer & Oncology Authors: Sandra Stickler Barbara Rath Gerhard Hamilton Source Type: research
Circ_0003855 involvement of esophageal cancer progression through miR-622/FLOT1
Oncol Res. 2024 Apr 23;32(5):925-931. doi: 10.32604/or.2023.042447. eCollection 2024.ABSTRACTTo confirm the relationship between Circ_0003855 and EC, we purchased the Human esophageal carcinoma cell line Eca109 and normal human esophageal epithelial cells HEEC, and the expression levels of Circ_0003855, miR-622, and FLOT1 were detected. The results show that Circ_0003855 and FLOT1 were highly expressed in Eca109 cells, while miR-622 was lowly expressed (p < 0.05). Subsequently, Circ_0003855 small interfering RNA (si-Circ_0003855) and its negative control (si-NC) were used to detect changes in cellular biological behavio...
Source: Oncology Research - April 30, 2024 Category: Cancer & Oncology Authors: Jingjing Tian Xibao Hu Xinrong Zhang Source Type: research
A review on potential heterocycles for the treatment of glioblastoma targeting receptor tyrosine kinases
Oncol Res. 2024 Apr 23;32(5):849-875. doi: 10.32604/or.2024.047042. eCollection 2024.ABSTRACTGlioblastoma, the most aggressive form of brain tumor, poses significant challenges in terms of treatment success and patient survival. Current treatment modalities for glioblastoma include radiation therapy, surgical intervention, and chemotherapy. Unfortunately, the median survival rate remains dishearteningly low at 12-15 months. One of the major obstacles in treating glioblastoma is the recurrence of tumors, making chemotherapy the primary approach for secondary glioma patients. However, the efficacy of drugs is hampered by the...
Source: Oncology Research - April 30, 2024 Category: Cancer & Oncology Authors: Nilam Bhusare Maushmi Kumar Source Type: research
